Abstract:Background Targeting the ubiquitin-proteasome pathway is a promising approach for anticancer strategies. Recently, we found Bik accumulation in cancer cell lines after they were treated with bortezomib. However, recent evidence indicates that proteasome inhibitors may also induce the accumulation of anti-apoptotic Bcl-2 family members. The current study was designed to analyze the levels of several anti-apoptotic members of Bcl-2 family in different human cancer cell lines after they were treated with proteasome inhibitors. Methods Different human cancer cell lines were treated with proteasome inhibitors. Western blot were used to investigate the expression of Mcl-1 and activation of mitochondrial apoptotic signaling. Cell viability was investigated using SRB assay, and induction of apoptosis was measured using flow cytometry. Results We found elevated Mcl-1 level in human colon cancer cell lines DLD1, LOVO, SW620, and HCT116; human ovarian cancer cell line SKOV3; and human lung cancer cell line H1299, but not in human breast cancer cell line MCF7 after they were treated with bortezomib. This dramatic Mcl-1 accumulation was also observed when cells were treated with other two proteasome inhibitors, MG132 and calpain inhibitor I (ALLN). Moreover, our results showed Mcl-1 accumulation was caused by stabilization of the protein against degradation. Reducing Mcl-1 accumulation by Mcl-1 siRNA reduced Mcl-1 accumulation and enhanced proteasome inhibitor-induced cell death and apoptosis, as evidenced by the increased cleavage of caspase-9, caspase-3, and poly (ADP-ribose) polymerase. Conclusions Our results showed that it was not only Bik but also Mcl-1 accumulation during the treatment of proteasome inhibitors, and combining proteasome inhibitors with Mcl-1 siRNA would enhance the ultimate anticancer effect suggesting this combination might be a more effective strategy for cancer therapy.

Bik/NBK Accumulation Correlates with Apoptosis-Induction by Bortezomib (PS-341, Velcade) and Other Proteasome Inhibitors

Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors

Overcoming Acquired TRAIL Resistance in Human Colon Cancer by Proteasome Inhibitor Bortezomib

Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.

SUMOylation Plays a Role in Gemcitabine- and Bortezomib-Induced Cytotoxicity in Human Oropharyngeal Carcinoma KB Gemcitabine-Resistant Clone.

[Apoptosis in Jurkat Cells Induced by Bortezomib Combined with Adriamycin].

Proteasome inhibition induces apoptosis through simultaneous inactivation of MCL-1/BCL-XL by NOXA independent of CHOP and JNK pathways

[Effects of Proteasome Inhibitor Bortezomib on NF-kappaB Activity and ICAM-1 Mrna Expression of K562 Cells].

Antitumor Activity and Drug Interactions of Proteasome Inhibitor Bortezomib in Human High-Risk Myelodysplastic Syndrome Cells.

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Bortezomib induces apoptosis in human neuroblastoma CHP126 cells.

Induction of Apoptosis and Accumulation of P27kip1 Protein by Proteasome Inhibitor MG132 in Human Osteosarcoma MG-63 Cells

Synergistic Action of 5Z-7-oxozeaenol and Bortezomib in Inducing Apoptosis of Burkitt Lymphoma Cell Line Daudi

Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma

Cathepsin B and Its Interacting Proteins, Bikunin and TSRC1, Correlate with TNF-induced Apoptosis of Ovarian Cancer Cells OV-90.

Bortezomib Induces Apoptosis and Autophagy in Osteosarcoma Cells Through Mitogen-Activated Protein Kinase Pathway in Vitro

[Induction of Apoptosis in Leukemic Cells by Inhibiting the Ubiquitin-Proteasome Pathway and Its Possible Mechanism]

Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.

Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors

Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins

Molecular Mechanisms of Converting K562/DNR Cellular Drug-Resistance by Bortezomib.